{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-004159","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2025-01-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.307161+00:00","generated_at":"2026-05-28T00:06:20.136794+00:00","sec_items":["1.01","3.02","3.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Outlook Therapeutics raises ~$20.5M via warrant inductions; ONS-5010 meets noninferiority at week 12 in AMD trial","bullets":["Exercised existing warrants for ~$17.8M gross (including $8.7M from GMS Ventures) and ~$2.7M from Syntone.","Issued inducement warrants for 14.1M shares (Tranche A immediate, Tranche B subject to shareholder approval) at $2.26 exercise price.","In NORSE EIGHT, ONS-5010 showed +5.5 letters BCVA improvement at week 12, meeting noninferiority (p=0.0043) vs ranibizumab.","Plans to resubmit BLA for ONS-5010 in Q1 2025 based on complete 12-week safety and efficacy data.","No retinal vasculitis reported; safety profile comparable to ranibizumab across all study timepoints."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-004159","json":"https://secwatch.observer/filing/0001104659-25-004159.json","markdown":"https://secwatch.observer/filing/0001104659-25-004159.md","text":"https://secwatch.observer/filing/0001104659-25-004159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925004159/0001104659-25-004159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925004159/tm253522d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T00:06:20.136794+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}